tiprankstipranks
Alnylam Pharmaceuticals presents results from KARDIA-2 Phase 2 study
PremiumThe FlyAlnylam Pharmaceuticals presents results from KARDIA-2 Phase 2 study
26d ago
Roche, Alnylam report KARDIA-2 study met primary endpoint
PremiumThe Fly
Roche, Alnylam report KARDIA-2 study met primary endpoint
2M ago
Alnylam reports KARDIA-2  zilebesiran study met primary endpoint of lower SBP
PremiumThe Fly
Alnylam reports KARDIA-2 zilebesiran study met primary endpoint of lower SBP
2M ago
Alnylam price target lowered to $283 from $284 at Canaccord
PremiumThe FlyAlnylam price target lowered to $283 from $284 at Canaccord
3M ago
Alnylam price target lowered to $283 from $284 at Canaccord
PremiumThe Fly
Alnylam price target lowered to $283 from $284 at Canaccord
3M ago
Intellia Therapeutics price target lowered to $24 from $38 at Baird
PremiumThe Fly
Intellia Therapeutics price target lowered to $24 from $38 at Baird
3M ago
Alnylam initiated with a Peer Perform at Wolfe Research
PremiumThe FlyAlnylam initiated with a Peer Perform at Wolfe Research
3M ago
Alnylam price target lowered to $176 from $184 at Morgan Stanley
PremiumThe Fly
Alnylam price target lowered to $176 from $184 at Morgan Stanley
3M ago
Is ALNY a Buy, Before Earnings?
PremiumPre-Earnings
Is ALNY a Buy, Before Earnings?
3M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100